Menu
ETF
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow-12.01 M USD-10.91 M USD-16.44 M USD-26.97 M USD-27.28 M USD-18.86 M USD-18.28 M USD-14.48 M USD-8.44 M USD-6.51 M USD-4.34 M USD-2.19 M USD
Depreciation & Amortization2.79 M USD2.15 M USD485641 USD105123 USD
Stock-Based Compensation537540 USD245864 USD858269 USD5.34 M USD5.96 M USD5.23 M USD5.36 M USD16.35 M USD2.74 M USD1.56 M USD1.71 M USD1.39 M USD
Capital Expenditures374983 USD147668 USD0 USD
Cash Flow from Investing18.66 M USD-4.95 M USD-3.13 M USD-10.43 M USD-374983 USD-147668 USD0 USD
Cash Flow from Financing9.86 M USD14.99 M USD1.11 M USD202130 USD52.56 M USD6.74 M USD816477 USD71.25 M USD5.72 M USD7.78 M USD10.78 M USD2.28 M USD
Dividends Paid
Stock Buybacks71710 USD310493 USD0 USD
Free Cash Flow-18.66 M USD-14.63 M USD-8.44 M USD

Marker Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapeutic solutions in the pharmaceuticals and biotech sector. Headquartered in Houston, Texas, and founded in 1999, the company specializes in advancing treatments designed to address significant unmet medical needs. Marker Therapeutics operates within the competitive biotechnology industry, where it engages in research, development, and commercialization of therapeutic products. The company's work spans clinical and preclinical stages, targeting disease areas where novel biological approaches can provide meaningful patient benefits. As a publicly traded biotechnology firm, Marker Therapeutics is subject to the rigorous regulatory and scientific standards that govern drug development and approval. The company maintains operations focused on translating scientific discoveries into effective treatments, contributing to the broader landscape of modern therapeutic innovation and advancing healthcare solutions.